Wierda WG - Search Results

1

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.

Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ; Chronic Lymphocytic Leukemia Research Consortium. Tsimberidou AM, et al. Among authors: wierda wg. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):568-74. doi: 10.1016/j.clml.2013.03.012. Epub 2013 Jun 27. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23810245 Free PMC article. Clinical Trial.

2

Chronic lymphocytic leukemia.

Wierda WG, Kipps TJ. Wierda WG, et al. Curr Opin Hematol. 1999 Jul;6(4):253-61. doi: 10.1097/00062752-199907000-00010. Curr Opin Hematol. 1999. PMID: 10400375 Review.

3

CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.

Chu P, Wierda WG, Kipps TJ. Chu P, et al. Among authors: wierda wg. Blood. 2000 Jun 15;95(12):3853-8. Blood. 2000. PMID: 10845920 Free article.

4

Gene therapy of hematologic malignancies.

Wierda WG, Kipps TJ. Wierda WG, et al. Semin Oncol. 2000 Oct;27(5):502-11. Semin Oncol. 2000. PMID: 11049018 Review.

5

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. Wierda WG, et al. Blood. 2000 Nov 1;96(9):2917-24. Blood. 2000. PMID: 11049967 Free article. Clinical Trial.

6

Immunogenetic therapy for B-cell malignancies.

Kipps TJ, Chu P, Wierda WG. Kipps TJ, et al. Among authors: wierda wg. Semin Oncol. 2000 Dec;27(6 Suppl 12):104-9. Semin Oncol. 2000. PMID: 11225994 Review.

7

T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154.

Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. Cantwell MJ, et al. Among authors: wierda wg. Leukemia. 2001 Sep;15(9):1451-7. doi: 10.1038/sj.leu.2402208. Leukemia. 2001. PMID: 11516107

8

Immunotherapy of chronic lymphocytic leukemia.

Wierda WG, O'Brien S. Wierda WG, et al. Expert Rev Anticancer Ther. 2001 Jun;1(1):73-83. doi: 10.1586/14737140.1.1.73. Expert Rev Anticancer Ther. 2001. PMID: 12113136 Review.

9

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Kantarjian HM, et al. Clin Cancer Res. 2002 Jul;8(7):2167-76. Clin Cancer Res. 2002. PMID: 12114417 Clinical Trial.

10

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Faderl S, et al. Blood. 2003 May 1;101(9):3413-5. doi: 10.1182/blood-2002-07-1952. Epub 2003 Jan 9. Blood. 2003. PMID: 12522009 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

544 results

Search Page

Filters